Clinical Trial Update: To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating SCTA01 for high-risk outpatients with COVID-19 is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2

Drugs mentioned

• SCTA01

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: COVID-19, SARS-CoV-2 | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING